Sarcomas are rare tumours, often with poor prognosis and for which few therapeutic options exist. The marked effect of immune checkpoint inhibitors targeting the PD1—PD-L1—CTLA-4 axes on the long-term survival of patients with other tumour types justified the initial enthusiasm for clinical trials evaluating immune checkpoint inhibitors in patients unstratified by sarcoma subtype. The results obtained with pembrolizumab1 and nivolumab, alone or in combination with ipilimumab,2 suggest that immune checkpoint inhibitors have promising efficacy in subgroups of patients within specific sarcoma subtypes.
[Comment] Immune checkpoint inhibition in sarcomas: time to be histology-specific?
Leggi l'articolo originale